Answers are grounded in this paper and cite their sources.
In order to assess the anti-inflammatory and therapeutic action of the probiotic, treated-yeast Milmed, twelve patients (age range 25-to-79 years) presenting IBS-IBD with a wide range of gut-intestinal symptoms, were studied. Each patient completed a questionnaire outlining demographic characteristics and test items regarding their health issues, both prior to and after the twelve-week period (on three occasions each week) of Milmed intervention. Patients’ accounts of their symptom-profiles were quantified and subjected to statistical analyses. It was observed that in comparison with the placebo (administered untreated-yeast) control, the Milmed group reported fewer symptoms, following treatment, as well as also fewer symptoms compared to their pre-treatment report. Untreated-yeast administration to patients did not induce any reduction of IBS-IBD symptoms. There was no correlation between patients’ responses regarding symptoms Before and After intervention. It is possible that increasing the number of capsules ingested per week, from 3/week to 1/day, may have provided the patients with greater benefits. Despite certain limitations of this study when taken together with the reported anti-inflammatory propensity of Milmed upon glial and neuronal cell cultures in vitro, these findings imply several useful therapeutic applications for the treated-yeast, Milmed, in the treatment of gut-intestinal conditions, such as IBS-IBD and other related ailments.
No takes yet. Share an insight, caveat, or question.
Trevor Archer (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: